Genenta Science S.p.A.
GNTA · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | -0.17 | 0.18 | 0.15 |
| FCF Yield | -0.01% | -8.12% | -0.00% | -0.00% |
| EV / EBITDA | -15.12 | -13.83 | -10.28 | -15.86 |
| Quality | ||||
| ROIC | -16.95% | -41.18% | -26.52% | -23.93% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.44 | 0.70 | 0.51 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 99.91% | -302,937.91% | 43.19% | 99.95% |
| Safety | ||||
| Net Debt / EBITDA | -0.71 | 0.87 | 1.37 | 0.75 |
| Interest Coverage | -7.92 | -21.42 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -635.63 |